semaglutide (Ozempic, Wegovy, Rybelsus): the GLP-1 agonist reshaping obesity medicine

semaglutide is a 31-amino-acid GLP-1 receptor agonist engineered by Novo Nordisk for once-weekly dosing. its five FDA-approved indications span type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease protection, and metabolic liver disease, making it the most broadly approved incretin peptide in clinical use as of 2026.

what is semaglutide?

semaglutide is approximately 94% homologous to native human GLP-1, with two deliberate molecular changes that transform a short-lived gut hormone into a weekly medicine. a substitution at position 8 blocks the DPP-4 enzyme that would otherwise destroy the peptide within minutes. a C18 fatty diacid side chain attached at lysine-26 binds tightly to serum albumin, extending the effective half-life to approximately one week and supporting once-weekly subcutaneous dosing.

the drug is marketed under three brand names with different indications and delivery methods. Ozempic (subcutaneous injection, weekly) is indicated for glycemic control in type 2 diabetes and, since January 2025, for reducing eGFR decline and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1]. Wegovy (subcutaneous injection, weekly, higher dose) is indicated for chronic weight management and, since March 2024, for reducing major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease, and since August 2025 for treatment of MASH with moderate-to-advanced liver fibrosis [2]. Rybelsus (oral tablet) is indicated for glycemic control in type 2 diabetes; its bioavailability is low (~0.4-1%) but sufficient for clinical effect when taken with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer [3].

how does it work?

semaglutide activates GLP-1 receptors throughout the body in a glucose-dependent manner. in the pancreas, it amplifies insulin secretion when blood glucose is elevated and suppresses inappropriate glucagon release. in the gut, it delays gastric emptying, especially early in treatment. in the brain, it reduces appetite and caloric intake through central satiety signaling. the combination of these effects produces meaningful weight loss and cardiometabolic improvement that extends well beyond glycemic control.

the cardiovascular and kidney benefits observed in outcomes trials likely reflect multiple concurrent mechanisms: body-weight reduction, glycemic improvement, blood pressure lowering, and possible direct GLP-1 pathway effects on vascular and inflammatory biology. the exact proportional contribution of weight-loss-dependent versus weight-loss-independent mechanisms has not been fully resolved, and this remains an active area of investigation. protein binding greater than 99% accounts for the prolonged systemic exposure that makes once-weekly dosing practical for the injectable formulations.

what do the major trials show?

semaglutide's trial program is one of the most extensive in modern peptide pharmacology. the STEP 1 obesity trial, the SELECT cardiovascular outcomes trial, the FLOW kidney outcomes trial, and the SUSTAIN diabetes program each added a distinct approved indication. together they represent tier 1, phase 3 RCT-grade evidence across multiple organ systems.

STEP 1 (NEJM 2021) randomized 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo plus lifestyle intervention for 68 weeks. mean body-weight change was approximately -15% in the semaglutide arm versus substantially less in the placebo arm, which was among the strongest single-agonist weight-loss signals seen at that time [4]. treatment discontinuation is commonly followed by partial weight regain, reinforcing that the drug works while being taken.

SELECT (NEJM 2023) randomized adults with obesity or overweight and established cardiovascular disease but without diabetes. major adverse cardiovascular events occurred in 6.5% on semaglutide versus 8.0% on placebo over the study period, a statistically significant reduction that led to the March 2024 FDA approval for cardiovascular risk reduction [5]. this moved semaglutide beyond metabolic endpoints to hard cardiovascular outcomes in a non-diabetes population.

FLOW (NEJM 2024) focused on adults with type 2 diabetes and chronic kidney disease. the primary composite kidney outcome had a hazard ratio of 0.76 (95% CI 0.66-0.88), demonstrating benefit that extends beyond glycemic endpoints in a population with established renal disease [6]. the January 2025 Ozempic label update incorporated this kidney outcome indication.

in type 2 diabetes, the SUSTAIN and PIONEER programs consistently demonstrated HbA1c reduction and weight benefit versus comparators across both injectable and oral semaglutide. SUSTAIN 6 reported reduced first major adverse cardiovascular events versus placebo (hazard ratio 0.74, 95% CI 0.58-0.95) in patients with type 2 diabetes and established cardiovascular risk, but also showed increased diabetic retinopathy complications (hazard ratio 1.76) linked in part to rapid glycemic change in vulnerable patients -- a safety signal that remains in the label [7]. the MASH approval in August 2025 was based on histology-based RCT data showing MASH resolution without worsening fibrosis in 62.9% of semaglutide-treated patients versus 34.3% with placebo at 72 weeks, which met accelerated-approval criteria pending confirmatory outcomes data.

safety profile and key risks

gastrointestinal events dominate the tolerability profile: nausea, vomiting, diarrhea, constipation, and abdominal pain, which vary by dose and escalation speed and are the most common reason for discontinuation. serious but less frequent risks include pancreatitis, gallbladder disease, dehydration-related acute kidney injury in the setting of severe GI losses, and worsening of diabetic retinopathy in vulnerable patients undergoing rapid glycemic improvement.

the semaglutide label (like all GLP-1 agonist labels) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies; human relevance is not established, but the label contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. weight-loss use is not recommended in pregnancy, and the long elimination half-life means the label advises discontinuation well before planned conception [3]. delayed gastric emptying may alter absorption kinetics of oral co-medications, which is relevant for patients on drugs with narrow therapeutic index.

semaglutide versus tirzepatide and the incretin landscape

semaglutide activates only the GLP-1 receptor. tirzepatide adds GIP receptor co-activation and biased GLP-1 receptor signaling, producing greater mean weight loss in head-to-head comparisons. semaglutide currently leads on breadth of approved indications, oral formulation availability, and longer post-approval safety experience.

SURMOUNT-5 (NEJM May 2025), the first head-to-head obesity trial at maximum approved doses, reported mean weight loss of 20.2% for tirzepatide versus 13.7% for semaglutide 2.4 mg over 72 weeks, with tirzepatide also showing lower GI-related discontinuation at maximum doses. for type 2 diabetes glycemic control, SURPASS-2 showed greater HbA1c reduction with tirzepatide versus semaglutide 1 mg. however, semaglutide currently has approved indications for CKD risk reduction, MASH, and cardiovascular risk reduction in non-diabetes obesity that tirzepatide does not yet hold, as well as a decade-longer track record in clinical practice.

liraglutide is the older once-daily GLP-1 comparator; semaglutide generally provides higher efficacy with lower dosing frequency. the next generation of incretin agents, including retatrutide (a triple GIP/GLP-1/glucagon agonist in phase 3), is pushing the weight-loss ceiling further. for a broader map of how the GLP-1 family connects to the GH axis that includes tesamorelin and ipamorelin, the underlying biology is covered in our free peptides and your body module.